According to Immutep's latest financial reports the company's current revenue (TTM) is -$0.01 M. In 2022 the company made a revenue of $0.11 M an increase over the years 2021 revenue that were of N/A.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2022 | $0.11 M | INF% |
2021 | N/A | -100% |
2020 | $5.14 M | 5140.34% |
2019 | $0.09 M | -94.96% |
2018 | $1.94 M | INF% |
2017 | N/A | -100% |
2016 | $0.13 M | INF% |
2015 | N/A | NAN% |
2014 | N/A | NAN% |
2013 | N/A | -100% |
2012 | $1.55 M | INF% |
2011 | N/A | -100% |
2010 | $0.44 M | INF% |
2009 | N/A | NAN% |
2008 | N/A |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
![]() Illumina ILMN | $4.44 B | -1,599,640,387.77% | ๐บ๐ธ USA |
![]() FibroGen FGEN | $0.11 B | -41,751,538.85% | ๐บ๐ธ USA |
![]() HTG Molecular Diagnostics
HTGM | $6.36 M | -2,290,107.19% | ๐บ๐ธ USA |